Neil J. Campbell, President & CEO of Helomics, said, “The DEFENDER Live Cell Liquid Biopsy System is an important clinical research and soon to be clinical tool that will lead to a better understanding of the biophysical processes involved in tumor cell shedding, and to the rapid identification and development of new anti-cancer therapies, new treatment markers, and companion diagnostics. read more
The next generation in Personalized Healthcare™
Personalized healthcare should be comprehensive, precise, predictive, but most importantly, personal.
We believe that each patient is unique, and their cancer treatment should be too.
Helomics' ongoing array of multiple products and technologies provide unique clinical value through a Comprehensive Tumor Profile.
peer reviewed publications and
abstracts on ChemoFx
gynecologic cancer specimens received for ChemoFx testing
physicians have sent for ChemoFx testing
unique sets of gynecologic cancer cell specimens in our Biorepository